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background:  DMD is the most common muscular dystrophy characterized by absence of dystrophin. A significant cardiomyopathic 
phenotype has emerged as a leading cause of death in DMD. There is limited knowledge about DMD cardiomyopathy due to limited 
access to human cardiac tissue. We hypothesized the pathophysiology of DMD cardiomyopathy can be modeled by utilizing DMD hiPSC 
cardiomyocytes (CM) and interrogating them at the cellular and molecular level.
Methods:  Dermal fibroblasts were obtained from patients with DMD cardiomyopathy and normal healthy controls. The fibroblasts were 
reprogrammed to hiPSC using retroviral vectors containing the human transcription factors, OCT4, SOX2, KLF4 and C-MYC. The DMD and 
control hiPSC lines were differentiated to CM using a directed differentiation protocol. Molecular and physiologic assays were performed at 
day 30 of differentiation.
results:  DMD and control hiPSC lines expressed pluripotent markers, formed teratomas, and were karyotypically normal. The DMD 
hiPSC CM demonstrated DYSTROPHIN exon deletions consistent with patient dystrophin deletions (patient 1: exon deletion 3-7; patient 
2 exon deletions 4-43). Both DMD and control hiPSC differentiated to beating, electrically coupled CM sheets. Western blot analysis 
demonstrated dystrophin band at 427kDa in all control hiPSC CM and absence in DMD hiPSC CM. Dystrophin is associated with the 
dystroglycan complex in all control hiPSC CM and absent in DMD hiPSC CM as assayed by wheat germ agglutinin co-immunoprecipitation 
of beta-dystroglycan and dystrophin at d30. Increased membrane fragility, a hallmark feature of DMD, was observed by increased release 
of CK-MB in DMD hiPSC CM.
conclusion:  Our results suggest that DMD hiPSC can be differentiated to CM and have a unique phenotype for disease investigation. 
Further evaluation of the molecular and physiologic phenotype of DMD hiPSC cardiomyocytes will serve as a platform for developing novel 
therapies for patients with DMD cardiomyopathy.
